Turning Promising Peptides into Groundbreaking Therapeutics for Chronic Diseases

 We are comprised of a dedicated group of scientists focused on developing next-generation therapeutics to treat chronic diseases. 

We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for multiple chronic diseases.  

At Antlia Bioscience, we are driven to make a profound difference in the treatment of cardiovascular and pulmonary diseases. Our work is supported by world-class advisors and collaborators who are all aligned with our vision to bring life-changing therapies to the market. 

We currently have three different therapeutic programs in development, all of which have shown exceptional potential as therapeutics for multiple chronic diseases with unmet medical needs.